Getting Patients Started With TEPEZZA

TEPEZZA is a prescription medication administered via infusion. A full course of treatment with TEPEZZA is 8 infusions, given once every 3 weeks.1 TEPEZZA may be administered at an infusion center, your practice, a hospital, or your patient’s home.

Before beginning the enrollment steps below, make sure your patients understand that:

  • TEPEZZA is a specialty medicine and may require extra insurance approvals that can often take 30 to 90 days, or longer
  • TEPEZZA is an intravenous medicine and the full course of treatment is 8 infusions1
  • While many patients have less proptosis, redness, pain, and swelling as soon as 6 weeks after treatment with TEPEZZA, it is recommended that they receive the full course of treatment, as improvement continues across all 8 infusions1,2

Steps to starting a patient on TEPEZZA:

Checklist image Checklist image Checklist image

Step 1: Gather clinical information on patient’s Thyroid Eye Disease (TED) diagnosis. Download and review the prior authorization (PA) form and requirements from the payor website.

Checklist image Checklist image Checklist image

Step 2: Initiate patient enrollment. Complete the PDF or DocuSign® option of the Patient Enrollment Form (PEF) to get your patient started on TEPEZZA. To complete the PEF, both a physician signature and a patient signature are required.


 

Checklist image Checklist image Checklist image

Step 3: Review patient’s benefits investigation and payor requirements. Identify a site of care (SOC).

Checklist image Checklist image Checklist image

Step 4: Coordinate submission of prior authorization with SOC.

Checklist image Checklist image Checklist image

Step 5: Confirm your patient has scheduled their first infusion appointment after PA approval.

Helpful Resource:

The TEPEZZA Access Roadmap provides more detailed information on the steps to follow to get your patients started on TEPEZZA. Download.

Support for patients on TEPEZZA:

Horizon believes cost should never stop someone from getting the medicine they need. Support for your patients is available from Horizon By Your Side.


Key considerations when starting a patient on TEPEZZA1:

  • Educate and counsel females of reproductive potential about the need to use effective contraception prior to initiation, during treatment with TEPEZZA, and for 6 months after the last dose1
  • Patient’s glucose levels should be monitored for hyperglycemic reactions1
  • Patients with preexisting diabetes or impaired glucose tolerance should be under appropriate glycemic control before receiving TEPEZZA1
Dosage admin info Dosage admin info

Dosage and administration information

Learn about dosing and administration for TEPEZZA

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

Please see Full Prescribing Information for more information.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

Please see Full Prescribing Information for more information.

1. TEPEZZA (teprotumumab-trbw) [prescribing information] Horizon. 2. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761.